Dr. Bin Wang is the director of National Engineering Lab of Therapeutic Vaccines and a distinguished professor at Fudan University Shanghai Medical College. His research area is to focus on the effects of therapeutic vaccination to activate T cell or suppress T cells and the mechanism of immune regulations. He recently has developed a novel adjuvanted HBV therapeutic vaccine against chronic HBV, and develop an immunotolerogenic vaccine technology against autoimmune diseases, including type 1 diabetes, asthma and allergy.

He received his B.A. in biology from Shandong University in 1982 and his Ph.D. from the University of Cincinnati School of Medicine in 1990. He completed his postdoc training in virology and immunology at the Wistar Institute 1992 when he first demonstrated DNA vaccination against HIV-1 in clinical trials. He became an instructor and then assistant professor at University of Pennsylvania Medical School in the period of 1993 to 1998. He was a professor and served as the Chairman at Department of Microbiology and Immunology for 6 years at College of Biological Sciences, China Agricultural University before he joined to Fudan University. He has published over 130 peer-review articles and awarded 10 US and 12 Chinese patents. He serves as editorial board members for several international journals and executive members in number of scientific societies. 

Homepage: http://www.klmmv.fudan.edu.cn/bwlab/

LinkedIn: Bin Wang